<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059523</url>
  </required_header>
  <id_info>
    <org_study_id>SGT-65-03</org_study_id>
    <nct_id>NCT04059523</nct_id>
  </id_info>
  <brief_title>MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3</brief_title>
  <official_title>A Phase 1b, Multicenter, Open-Label, Parallel-Group, Maximal Use Systemic Exposure (MUSE) Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 Compared to Retin-A® 0.1% in Subjects With Moderate to Severe Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sol-Gel Technologies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sol-Gel Technologies, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the degree of systemic exposure of S6G5T-3 compared to the Reference Listed Drug
      (RLD) Retin-A® 0.1% Cream when applied topically once daily for 14 days, under maximal use
      conditions in adolescents ≥12 years of age and adults with acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Actual">February 6, 2020</completion_date>
  <primary_completion_date type="Actual">February 6, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of S6G5T-3 as measured by the maximum observed plasma concentration</measure>
    <time_frame>14 days</time_frame>
    <description>The degree of systemic exposure of S6G5T-3 compared to the Reference Listed Drug (RLD) when applied topically once daily for 14 days, under maximal use conditions in subjects with acne vulgaris. Cmax = Maximum plasma concentration will be calculated</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>S6G5T-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retin-A® 0.1% Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>topical cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S6G5T-3</intervention_name>
    <description>once daily</description>
    <arm_group_label>S6G5T-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retin-A® 0.1% Cream</intervention_name>
    <description>once daily</description>
    <arm_group_label>Retin-A® 0.1% Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects 9 years of age or older.

          2. Subject must consent to participate, verified by signing an approved written Informed
             Consent Form (ICF).

          3. Subjects must be generally healthy and free from any clinically significant disease,
             other than acne vulgaris, that might interfere with the study evaluations

          4. All females of child-bearing potential and premenarchal, excluding women who are
             surgically sterile

        Exclusion Criteria:

          1. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne etc.) or
             severe acne requiring systemic treatment.

          2. Underlying disease which requires the use of topical or systemic therapy which may
             confound study results or make results difficult to interpret.;

          3. Subjects unable to communicate well with the site study team (i.e., language problem,
             poor mental development or impaired cerebral function).

          4. Any other factor that, in the opinion of the Investigator, would prevent the subject
             from complying with the requirements of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

